If you have recently had bloodwork done or are considering a comprehensive hormone panel, you have probably seen markers like total testosterone, free testosterone, and SHBG listed. But what do these numbers actually mean? And more importantly, how do you know if your levels are truly optimal versus just "within range"?
Total Testosterone vs. Free Testosterone
Total testosterone measures the entire amount of testosterone circulating in your blood. This includes testosterone that is bound to sex hormone-binding globulin (SHBG), testosterone bound to albumin, and a small percentage that floats freely. Most standard lab panels only check total testosterone, but this gives you an incomplete picture.[1]
Free testosterone, typically only 2-3% of total testosterone, is the fraction that is biologically active. It can enter cells, bind to androgen receptors, and drive the physiological effects you associate with healthy testosterone levels: energy, muscle maintenance, mood stability, and libido. Two men can have the same total testosterone level, yet one may feel great while the other experiences symptoms of low T, simply because their free testosterone levels differ.[5]
The Age-Related Decline
Research from the Baltimore Longitudinal Study of Aging shows that total testosterone declines approximately 1.6% per year after age 30, while free testosterone drops even faster at 2-3% per year. Data from the Massachusetts Male Aging Study, tracking 1,709 men aged 40 to 70, confirmed this trajectory with both cross-sectional and longitudinal measurements.
Perhaps more striking, population-level testosterone has declined approximately 1% per calendar year independent of aging — meaning a 50-year-old man today has significantly lower testosterone than a 50-year-old man two decades ago. Environmental factors including endocrine disruptors, obesity prevalence, and lifestyle shifts are suspected contributors.
A large-scale study of men aged 45 and older found that 38.7% had total testosterone below 300 ng/dL, with obesity and diabetes doubling the odds.
Understanding SHBG
Sex hormone-binding globulin is a protein produced by the liver that binds to testosterone and makes it unavailable for use by your tissues. When SHBG is high, more of your testosterone is bound up and inactive, which can lead to symptoms of low testosterone even when your total number looks normal on paper. SHBG rises with age, making free and bioavailable testosterone more clinically relevant than total T in older men.[1] Factors that increase SHBG include aging, hyperthyroidism, liver disease, and certain medications. Conversely, insulin resistance, obesity, and hypothyroidism tend to lower SHBG.
What Are Optimal Ranges?
Standard laboratory reference ranges for total testosterone are extremely broad, often spanning 264 to 916 ng/dL. These ranges are derived from the general population, which includes men of all ages and health statuses. A 30-year-old with a total testosterone of 300 ng/dL would be told he is "within range," yet this level is in the bottom percentile for his age group and is often associated with fatigue, reduced motivation, and body composition changes.
The Endocrine Society guidelines recommend measuring testosterone in the morning before 10 AM when levels peak, and require two separate low readings for a diagnosis of hypogonadism.[5] At TotalVirility, we use evidence-based optimal ranges that account for age, context, and the interplay between biomarkers. For most men in their 30s and 40s, optimal total testosterone is typically between 500 and 900 ng/dL, with free testosterone above 15 pg/mL and SHBG between 20 and 50 nmol/L.
The Metabolic Connection
Testosterone and metabolic health are deeply intertwined. Research has shown that more than one-third of men with type 2 diabetes have low testosterone, and obesity doubles the risk of hypogonadism. This creates a vicious cycle: low testosterone promotes fat accumulation and insulin resistance, which in turn further suppresses testosterone production.
Beyond Testosterone: The Bigger Hormonal Picture
Testosterone does not exist in a vacuum. It interacts with estradiol, DHEA-S, LH, FSH, prolactin, and cortisol. A truly comprehensive picture requires testing multiple axes of the endocrine system. Elevated estradiol relative to testosterone can cause symptoms that mimic low T. High cortisol can suppress testosterone production. Low DHEA-S, a precursor hormone, can signal adrenal fatigue and overall hormonal decline.
This is why standard blood tests that only measure total testosterone and a basic metabolic panel often miss the full story. A comprehensive hormone panel gives you the data needed to make informed decisions about your health, whether that involves lifestyle changes, supplementation, or a conversation with an endocrinologist.
Key Takeaways
- Total testosterone alone is not enough. Free testosterone and SHBG provide critical context.[1]
- Testosterone declines ~1.6% per year after 30, and population levels have dropped ~1% per calendar year independent of aging.
- Standard lab reference ranges are too broad to assess individual optimization. Morning testing before 10 AM is recommended.[5]
- Metabolic health and testosterone are tightly linked — obesity and diabetes dramatically increase the odds of low T.
- Trends over time are more valuable than any single snapshot. Regular testing reveals the trajectory of your hormonal health.
References
- [1]
Vermeulen A, Verdonck L, Kaufman JM. “A critical evaluation of simple methods for the estimation of free testosterone in serum.” J Clin Endocrinol Metab (1999); 84(10):3666-3672.
PMID: 10523012 - [2]
Sniderman AD, Thanassoulis G, Glavinovic T, et al.. “Apolipoprotein B particles and cardiovascular disease: a narrative review.” JAMA Cardiol (2022); 7(12):1287-1295.
PMID: 36216435 - [3]
Ridker PM, Hennekens CH, Buring JE, Rifai N. “C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.” N Engl J Med (2000); 342(12):836-843.
PMID: 10733371 - [4]
Hollowell JG, Staehling NW, Flanders WD, et al.. “Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).” J Clin Endocrinol Metab (2002); 87(2):489-499.
PMID: 11836274 - [5]
Bhasin S, Brito JP, Cunningham GR, et al.. “Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline.” J Clin Endocrinol Metab (2018); 103(5):1715-1744.
PMID: 29562364